What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30

Summit Therapeutics (NASDAQ:SMMT) is one of the 15 large cap stocks under $30 with huge upside potential.

On March 16, Jefferies downgraded its rating for Summit Therapeutics Inc. (NASDAQ:SMMT) from Buy to Hold. The stock was also subject to a substantial target price revision by the firm, from $42 to $15. The firm lists four significant catalysts for Summit in 2026, each of which carries some risk.

Copyright: nexusplexus / 123RF Stock Photo

Jefferies also noted that, given the ambiguous translation from China to the rest of the world, a clean win is not an easy call for the HARMONi-6 reading. Although Summit Therapeutics Inc. (NASDAQ:SMMT) is the early mover and PD-1/VEGF appears to be a promising class, the firm seeks to find another way to play it.

Back on February 24, Summit Therapeutics (NASDAQ:SMMT) reported its fourth-quarter adjusted EPS of (14c), above the consensus of (1c), reflecting solid operational performance. The company provided updates on its global Phase III HARMONi-3 clinical trial, highlighting progress in both the squamous and non-squamous cohorts.

Screening for the squamous cohort has been completed during the first quarter of 2026, while enrollment for the non-squamous cohort is expected to finish in the second half of the year. Interim analyses for PFS and OS are planned at pre-specified milestones to ensure robust data assessment.

Summit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharma company that develops and commercializes medical oncology therapies. It is focused on developing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis in a single molecule. It is also running Phase III clinical trials for the treatment of non-small lung cancer.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.